Silence Therapeutics (NASDAQ:SLN) Cut to “Neutral” at HC Wainwright

HC Wainwright downgraded shares of Silence Therapeutics (NASDAQ:SLN) from a buy rating to a neutral rating in a report issued on Wednesday morning, MarketBeat reports. HC Wainwright currently has $20.00 price objective on the stock, down from their previous price objective of $75.00.

SLN has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating on the stock. William Blair cut Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday. Morgan Stanley raised their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, October 15th. Finally, Jefferies Financial Group cut Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price objective for the company. in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $24.00.

Silence Therapeutics Stock Up 0.1%

Shares of NASDAQ SLN opened at $19.67 on Wednesday. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $19.69. The firm has a 50-day moving average price of $12.90 and a 200 day moving average price of $10.08. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -15.37 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. Equities research analysts expect that Silence Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. 5AM Venture Management LLC acquired a new position in Silence Therapeutics during the second quarter worth about $5,228,676. SG Americas Securities LLC lifted its holdings in shares of Silence Therapeutics by 11.8% in the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after purchasing an additional 30,358 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Silence Therapeutics by 29.6% in the second quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock valued at $1,273,000 after purchasing an additional 26,449 shares in the last quarter. ADAR1 Capital Management LLC grew its position in shares of Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after purchasing an additional 148,514 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its position in shares of Silence Therapeutics by 6.2% in the first quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after purchasing an additional 9,159 shares during the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.

The company’s proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.